Information Provided By:
Fly News Breaks for April 8, 2016
ICPT
Apr 8, 2016 | 07:56 EDT
Cowen puts the chances of approval for Intercept's Ocaliva in PBC by its PDUFA date of May 29 at greater than 95%. The firm cited the FDA AdComm panelist's vote and commentary, as well as suggestions the agency is in discussions with the company already regarding labeling. Cowen reiterated its Outperform rating and $212 price target on Intercept shares.
News For ICPT From the Last 2 Days
There are no results for your query ICPT